These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 8073402)

  • 1. Factors affecting the restenosis rate after percutaneous transluminal coronary angioplasty.
    Bach R; Jung F; Kohsiek I; Ozbek C; Spitzer S; Scheller B; Dyckmans J; Schieffer H
    Thromb Res; 1994; 74 Suppl 1():S55-67. PubMed ID: 8073402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Failure of epoprostenol (prostacyclin, PGI2) to inhibit platelet aggregation and to prevent restenosis after coronary angioplasty: results of a randomised placebo controlled trial.
    Gershlick AH; Spriggins D; Davies SW; Syndercombe Court YD; Timmins J; Timmis AD; Rothman MT; Layton C; Balcon R
    Br Heart J; 1994 Jan; 71(1):7-15. PubMed ID: 8297699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Residual platelet function under acetylsalicylic acid and the risk of restenosis after coronary angioplasty.
    Terres W; Hamm CW; Ruchelka A; Weilepp A; Kupper W
    J Cardiovasc Pharmacol; 1992 Feb; 19(2):190-3. PubMed ID: 1376787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platelet aggregability and occurrence of restenosis following coronary angioplasty.
    Goel PK; Shahi M; Agarwal AK; Srivastava S; Seth PK
    Int J Cardiol; 1997 Aug; 60(3):227-31. PubMed ID: 9261632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty.
    Tsuchikane E; Fukuhara A; Kobayashi T; Kirino M; Yamasaki K; Kobayashi T; Izumi M; Otsuji S; Tateyama H; Sakurai M; Awata N
    Circulation; 1999 Jul; 100(1):21-6. PubMed ID: 10393676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trapidil (triazolopyrimidine), a platelet-derived growth factor antagonist, reduces restenosis after percutaneous transluminal coronary angioplasty. Results of the randomized, double-blind STARC study. Studio Trapidil versus Aspirin nella Restenosi Coronarica.
    Maresta A; Balducelli M; Cantini L; Casari A; Chioin R; Fabbri M; Fontanelli A; Monici Preti PA; Repetto S; De Servi S
    Circulation; 1994 Dec; 90(6):2710-5. PubMed ID: 7994812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Morphologic changes during follow-up after successful percutaneous transluminal coronary balloon angioplasty: quantitative angiographic analysis in 778 lesions--further evidence for the restenosis paradox. MERCATOR Study Group (Multicenter European Research trial with Cilazapril after Angioplasty to prevent Transluminal Coronary Obstruction and Restenosis).
    Hermans WR; Foley DP; Rensing BJ; Serruys PW
    Am Heart J; 1994 Mar; 127(3):483-94. PubMed ID: 8122593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Restenosis after transluminal coronary angioplasty: a risk factor analysis.
    Gürlek A; Dağalp Z; Oral D; Omürlü K; Erol C; Akyol T; Tutar E
    J Cardiovasc Risk; 1995 Feb; 2(1):51-5. PubMed ID: 7606641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of haematological parameters before coronary angioplasty on subsequent restenosis.
    Avci A; Boyaci A; Cağli K; Cosgun A; Gokce V; Duru E; Korkmaz S
    Acta Cardiol; 2004 Jun; 59(3):263-8. PubMed ID: 15255457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Restenosis after coronary angioplasty for rapidly progressive coronary stenosis.
    Bauters C; Passart F; Lablanche JM; McFadden EP; Hamon M; Bertrand ME
    Eur Heart J; 1996 Nov; 17(11):1671-7. PubMed ID: 8922915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient, lesion, and procedural variables as risk factors for luminal re-narrowing after successful coronary angioplasty: a quantitative analysis in 653 patients with 778 lesions. Multicenter European Research Trial with Cilazapril after Angioplasty to prevent Transluminal Coronary Obstruction and Restenosis (MERCATOR) Study Group.
    Hermans WR; Rensing BJ; Foley DP; Tijssen JG; Rutsch W; Emanuelsson H; Danchin N; Wijns W; Chappuis F; Serruys PW
    J Cardiovasc Pharmacol; 1993; 22 Suppl 4():S45-57. PubMed ID: 7523772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Restenosis after percutaneous transluminal coronary angioplasty in the elderly--risk factor analysis].
    Ishikawa Y; Fujioka Y; Kitagawa Y; Nobusawa A; Takahashi A; Taniguchi T; Yokoyama M
    Nihon Ronen Igakkai Zasshi; 1995 Jul; 32(7):491-6. PubMed ID: 7500552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Restenosis after successful percutaneous transluminal coronary angioplasty: the Montreal Heart Institute experience.
    Guiteras Val P; Bourassa MG; David PR; Bonan R; Crépeau J; Dyrda I; Lespérance J
    Am J Cardiol; 1987 Jul; 60(3):50B-55B. PubMed ID: 2956844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Restenosis following percutaneous transluminal angioplasty: clinical, physiologic and pathological features.
    Cox JL; Gotlieb AI
    CMAJ; 1986 May; 134(10):1129-32. PubMed ID: 2938706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of trapidil (triazolopyrimidine), a platelet-derived growth factor antagonist, in preventing restenosis after percutaneous transluminal coronary angioplasty.
    Okamoto S; Inden M; Setsuda M; Konishi T; Nakano T
    Am Heart J; 1992 Jun; 123(6):1439-44. PubMed ID: 1595521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of an acute reduction in lipoprotein(a) with coronary artery restenosis after percutaneous transluminal coronary angioplasty.
    Horie H; Takahashi M; Izumi M; Takaoka A; Fujita T; Sakamoto T; Kito O; Okamura H; Kinoshita M
    Circulation; 1997 Jul; 96(1):166-73. PubMed ID: 9236431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Restenosis after percutaneous transluminal coronary angioplasty in patients with non-insulin-dependent diabetes mellitus (NIDDM).
    Asakura Y; Suzuki M; Nonogi H; Haze K; Sato A; Inada H; Okuda Y; Yamashita K; Harano Y
    J Cardiovasc Risk; 1998; 5(5-6):331-4. PubMed ID: 9920005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipoprotein(a) in restenosis after percutaneous transluminal coronary angioplasty and coronary artery disease.
    Cooke T; Sheahan R; Foley D; Reilly M; D'Arcy G; Jauch W; Gibney M; Gearty G; Crean P; Walsh M
    Circulation; 1994 Apr; 89(4):1593-8. PubMed ID: 8149526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Restenosis after percutaneous transluminal coronary angioplasty.
    Kent KM
    Am J Cardiol; 1988 May; 61(14):67G-70G. PubMed ID: 2966567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of restenosis after coronary angioplasty. A study on demographic and metabolic variables.
    Johansen O; Abdelnoor M; Brekke M; Seljeflot I; Høstmark AT; Arnesen H
    Scand Cardiovasc J; 2001 Mar; 35(2):86-91. PubMed ID: 11405502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.